STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #665 by analyst upside · 2026-06-27
TRLV
Trulieve Cannabis Corp.
Healthcare · Market Cap $2B · P/E 0x
ANALYST PRICE TARGET
+133.6%
implied upside to consensus target
Current Price $8.99
Consensus Target $21.0
Bull Target $21.0
Bear Target $21.0
Analysts Covering 1
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
1
Hold
0
Sell
0
52-Week Low $3.5
52-Week High $13.28
YTD Return +3.3%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) N/A
Forward P/E 37.5x
EPS (TTM) $-0.40
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $1.2B
Profit Margin -6.9%
52-WEEK RANGE
52-Week Low $3.5
52-Week High $13.28
Current Price $8.99
Bear Target $21.0
Bull Target $21.0
● Now $8.99 ● Target $21.0
TRADING DATA
Avg Volume 905K
YTD Return +3.3%
Analyst Count 1
Consensus Buy
Upside to Target +133.6%
Last Updated 2026-06-27

ANALYST SUMMARY

Trulieve Cannabis Corp. (TRLV) is currently trading at $8.99 with a Wall Street consensus price target of $21.0, implying potential upside of 133.6% over the next 12 months. 1 analysts currently cover TRLV, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $21.0, while the most cautious has a target of $21.0.

TRLV operates in the Healthcare sector with a market capitalisation of $2B. The stock is up 3.3% year-to-date and is currently trading near the upper end of its 52-week range of $3.5 – $13.28.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
40
out of 100
Coverage depth
5/30
Consensus clarity
8/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →